Gufic Biosciences concluded its 42nd Annual General Meeting on September 4, 2026. The meeting was held via video conferencing in Mumbai.

The Board declared a 10% final dividend, amounting to ₹0.10 per equity share of face value ₹1 each, for the financial year ended March 31, 2026.

Key Resolutions

Shareholders approved several ordinary and special business items during the proceedings:

• Adoption of the audited standalone and consolidated financial statements for FY26.
• Re-appointment of Mr. Pranav J. Choksi as a director upon retirement by rotation.
• Ratification of remuneration for cost auditors M/s. Poddar & Co. for FY27.
• Re-appointment of Mr. Pankaj J. Gandhi as Whole Time Director and continuation of his directorship beyond age 70.

Meeting Details

Mr. Jayesh P. Choksi, Chairman & Managing Director, chaired the session. All directors and committee chairpersons were present. Statutory auditors, secretarial auditors, and the scrutinizer also attended.

A total of 43 shareholders participated, comprising 5 from the promoter group and 38 from the public category. Corporate shareholders holding 3,13,60,802 equity shares (representing 31.27% of paid-up capital) submitted authorized representations.

Ms. Ami Shah, Company Secretary & Compliance Officer, confirmed that remote e-voting was facilitated through NSDL. The audit reports for FY25-26 contained no qualifications or adverse remarks.

Gufic Biosciences promoted two senior executives to key leadership positions effective September 2, 2026. The board approved the changes following a recommendation from the Nomination & Remuneration Committee.

Ms. Ami Shah was promoted to Head-Legal while retaining her role as Company Secretary & Compliance Officer. Mr. Pinak Padhya was elevated from Vice President to President – Sales & Marketing.

Regulatory Disclosure

The company issued an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure complies with Part A of Schedule III of the Listing Regulations.

Executive Profiles

Ms. Shah holds a law degree (LL.B.) and is a qualified Company Secretary. She has served Gufic Biosciences for over 10 years. Her responsibilities include corporate governance, statutory compliance, and managing intellectual property matters.

Mr. Padhya brings over 28 years of experience in the pharmaceutical industry. He holds an MBA in Marketing and a Pharmacy Graduate degree. His previous roles include positions at Sun Pharma, Ranbaxy, Glenmark, Elder, Medley, and Cadila Pharma.

Key Responsibilities

Ms. Shah continues to serve as a Key Managerial Personnel. Her background includes drafting commercial agreements and handling litigation. She previously worked with the JM Baxi Group as Senior Executive – Secretarial Team.

Mr. Padhya’s expertise covers multiple therapeutic areas including Orthopaedics, Gastrointestinal, Gynaecology, Herbal, Dermatology, Pediatrics, and General Practice. He focuses on strategic brand building and cluster growth.